Evidence map›Paper›PMID 42470389›Full record

ArticleOrganic letters2026

Total Synthesis of JBIR-141 and Its Analogues: Potent Inhibitors of Forkhead Box O3 (FOXO3).

Hidetoshi Ban, Kotaro Yasoshima, Kosuke Ohsawa, Madoka Suzuki, Noritaka Kagaya, Teppei Kawahara, Hiroyuki Yamakoshi, Masahito Yoshida, Kazuo Shin-Ya, Takayuki Doi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Organic letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hidetoshi BanGraduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-aoba, Aramaki, Sendai980-8578, Japan.
Kotaro YasoshimaGraduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-aoba, Aramaki, Sendai980-8578, Japan.
Kosuke OhsawaGraduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-aoba, Aramaki, Sendai980-8578, Japan.
Madoka SuzukiDepartment of Chemistry, Institute of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki305-8571, Japan.
Noritaka KagayaTechnology Research Association for Next Generation Natural Products Chemistry, 2-4-7 Aomi, Koto-ku, Tokyo135-0064, Japan.
Teppei KawaharaJapan Biological Informatics Consortium (JBIC), 2-4-7 Aomi, Koto-ku, Tokyo135-0064, Japan.
Hiroyuki YamakoshiGraduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-aoba, Aramaki, Sendai980-8578, Japan.ORCID 0000-0002-9263-577X
Masahito YoshidaDepartment of Chemistry, Institute of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki305-8571, Japan.ORCID 0000-0002-0252-7637
Kazuo Shin-YaNational Institute of Advanced Industrial Science and Technology (AIST) , 2-4-7 Aomi, Koto-ku, Tokyo135-0064, Japan.ORCID 0000-0002-4702-0661
Takayuki DoiGraduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-aoba, Aramaki, Sendai980-8578, Japan.ORCID 0000-0002-8306-6819

Funding

Japan Agency for Medical Research and Development 25ama121038j0004Japan Society for the Promotion of Science JP23K24003Japan Society for the Promotion of Science JP25K02381Ministry of Education, Culture, Sports, Science and Technology JP24H01055
6 · The paper itself

Abstract

The total synthesis of JBIR-141 and its analogues was achieved through a convergent assembly of three fragments. This synthesis successfully addressed several challenges arising from a highly acid-sensitive oxazoline, a reactive nitrosohydroxyamino group, and an epimerization-prone tetramic acid. The developed synthetic route enabled access to 25-methyl/17-methyl derivatives as potent/stabilized FOXO3 inhibitors. This study provides a robust platform for structure-activity relationship studies and future target identification in chronic myelogenous leukemia therapeutics.

Indexed as

Forkhead Box Protein O3PyrrolidinesHumansMolecular StructurePyrrolidinonesStereoisomerismStructure-Activity RelationshipForkhead Box Protein O3FOXO3 protein, humanPyrrolidinesPyrrolidinonestetramic acid

Identifiers

PMID42470389
PMCPMC13435308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.